$PSNL

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.

Personalis (PSNL) stock rose 24.0% after securing a new $18.3M task order from the U.S. Department of Veterans Affairs' Million Veteran Program, bringing its total VA MVP contracts to $243.3M. The company projects $168.4M revenue and $27.7M earnings by 2029, despite ongoing losses. Tempus' pending acquisition of Personalis for $1.6B highlights its value in genomics and MRD capabilities.

Personalis Inc. (PSNL) fell 6% after Craig-Hallum downgraded it to hold from buy, citing an unlikely higher bid than its announced sale to Tempus AI (TEM). Tempus shares also dropped 7.2%.

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

Tempus AI agreed to acquire Personalis for $1.5B in July 2026. Personalis' tech supports Moderna and Merck's mRNA cancer vaccine, which showed positive Phase 3 results in August 2026. Tempus shares rose 23.91% on the news. Personalis' revenue grew 441.6% YoY in Q2 2026. Tempus reported $382.5M in Q2 2026 revenue, up 22% YoY. The deal is expected to close late Q4 2026 or early 2027.

Personalis (PSNL) reported Q2 2026 revenue of $22.36 million, up from $17.20 million a year earlier, but net loss widened to $31.68 million. For the first half of 2026, revenue was $37.83 million year on year, while net loss rose to $61.72 million. The article also notes Tempus AI’s deal to buy the remaining stake for about $1.6 billion.

Tempus AI (NASDAQ: TEM) shares rose about 12.6% in a weekly update after a $1.5B Personalis deal. The article cites strong AI healthcare adoption, gross margin of 73.5%, revenue around $1.27B, but negative EBIT margin of -14.4%. It highlights technical support near $47 and resistance around $55-$57.

Personalis (PSNL) reported Q2 2026 revenue of $22.36M, up from $17.20M a year earlier, but net loss widened to $31.68M and basic loss per share rose to $0.30 from $0.23. For H1 2026, revenue was about $37.83M, flat, while net loss grew to $61.72M. The company reaffirmed 2026 guidance of $78.0–80.0M revenue and about $105M net loss.

Personalis (Nasdaq: PSNL) reported Q2 2026 results for the quarter ended June 30. Clinical tests rose 199% to 10,384. Clinical revenue increased 442% to $2.6 million, while total revenue grew 30% to $22.4 million. The company said it secured Medicare coverage for NeXT Personal in additional IO and neoadjuvant breast cancer indications and ended the quarter with about $212.7 million in cash.

Personalis, Inc. (PSNL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Personalis Reports Second Quarter Results and Recent Highlights Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2 Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million Secured